hemophilia

5 FDA decisions to watch in the first quarter of 2025
BioPharma Dive
Mon, 01/6/25 - 06:54 pm
FDA
Vertex Pharmaceuticals
non-opioid pain treatments
suzetrigine
GSK
vaccines
MenABCWY
meningitis
Alnylam
vutrisiran
transthyretin amyloid cardiomyopathy
Soleno
diazoxide choline
Prader Willi syndrome
Sanofi
hemophilia
fitusiran
FDA approves drugs from Vertex, Novo, Bristol Myers to wrap 2024
BioPharma Dive
Thu, 01/2/25 - 11:35 am
FDA
Vertex Pharmaceuticals
Novo Nordisk
Bristol Myers Squibb
Alyftrek
cystic fibrosis
Alhemo
hemophilia
Opdivo Qvantiq
solid tumors
BioMarin preaches patience amid slow sales for hemophilia gene therapy
BioPharma Dive
Fri, 02/23/24 - 10:26 am
Biomarin
Roctavian
earnings
gene therapy
hemophilia
BioMarin secures hemophilia gene therapy coverage in Germany
BioPharma Dive
Wed, 11/29/23 - 11:35 pm
Biomarin
Roctavian
gene therapy
Germany
hemophilia
Roche scores—again—in hemophilia drug patent case against Takeda
Fierce Pharma
Thu, 09/21/23 - 11:47 am
Roche
Takeda
patents
legal
Genentech
Baxalta
hemophilia
Novo Nordisk's phase 3 data for hemophilia hopeful fail to shake off Pfizer's shadow
Fierce Biotech
Tue, 06/27/23 - 10:36 pm
Novo Nordisk
hemophilia
clinical trials
Pfizer
Roche
Hemlibra
Pfizer's hemophilia drug hits in phase 3, giving it a chance to leapfrog Novo Nordisk
Fierce Biotech
Tue, 05/30/23 - 10:07 am
Pfizer
Novo Nordisk
clinical trials
hemophilia
marstacimab
BioMarin's hemophilia gene therapy faces further delays over fresh FDA requests
Fierce Biotech
Tue, 11/8/22 - 10:46 am
Biomarin
gene therapy
FDA
hemophilia
Roctavian
Cost watchdog ICER backs multimillion-dollar price tags for BioMarin, CSL hemophilia gene therapies
Fierce Pharma
Thu, 11/3/22 - 11:02 am
ICER
drug pricing
gene therapy
Biomarin
CSL
Bluebird Bio
hemophilia
ICER Deems Hemophilia Gene Therapies Worth the $2.5M Price Tag
BioSpace
Thu, 09/15/22 - 10:14 am
hemophilia
gene therapy
ICER
Biomarin
Chugai
Roche
CSL Behring
Freeline's One Dose Gene Therapy could Transform Hemophilia B Treatment
BioSpace
Sun, 07/24/22 - 07:56 pm
hemophilia
hemophilia B
clinical trials
Freeline Therapeutics
gene therapy
FLT180a
Novo Nordisk A/S: Phase 3 data for concizumab show 86% reduction in treated bleeds in haemophilia A or B with inhibitors
Yahoo Finance
Sun, 07/10/22 - 11:51 pm
Novo Nordisk
concizumab
hemophilia
Fresh data show UniQure's hemophilia gene therapy appears to hold up
BioPharma Dive
Fri, 12/10/21 - 12:01 am
uniQure
gene therapy
hemophilia
hemophilia B
Pfizer tears up gene therapy timelines, revealing a series of phase 3 delays that end vision of a banner 2022
Fierce Biotech
Wed, 11/3/21 - 10:43 am
Pfizer
gene therapy
hemophilia
Duchenne Muscular Dystrophy
Sangamo Therapeutics
Takeda's Baxalta settles with Bayer over $173M hemophilia patent infringement verdict
Fierce Pharma
Wed, 05/19/21 - 11:05 pm
Baxalta
Takeda
hemophilia
patents
Bayer
Adynovate
FDA lifts clinical hold on uniQure's gene therapy amid cancer concerns; shares jump
Fierce Biotech
Mon, 04/26/21 - 12:06 pm
uniQure
hemophilia
gene therapy
FDA
Sanofi revises fitusiran dosing to cut risk of thrombotic events in hemophilia phase 3
Fierce Biotech
Mon, 02/8/21 - 10:41 am
Sanofi
fitusiran
hemophilia
hemophilia A
hemophila B
Gene therapy for hemophilia: So close, yet so far away
BioPharma Dive
Thu, 01/28/21 - 11:18 pm
hemophilia
hemophilia A
hemophilia B
gene therapy
Biomarin
uniQure
Novo invests in Hemab, a company going against the hemophilia gene therapy grain with a plan for bispecifics
Endpoints
Mon, 12/14/20 - 10:53 am
Novo Nordisk
Novo Holdings
Hemab
hemophilia
Sanofi accepts a lengthy delay as its hemophilia drug fitusiran resumes a PhIII after safety fears forced a halt
Endpoints
Thu, 12/10/20 - 07:20 pm
Sanofi
fitusiran
FDA
hemophilia

Pages